Posts by: Iqra Mumal

A gene therapy revolving around a chromosome-protecting enzyme could be a way to treat pulmonary fibrosis, Spanish researchers report. Proper levels of the enzyme, telomerase, are necessary to generate the right ... Read more

February 5, 2018February 5, 2018

Vertex Selects VX-659 and VX-445 for Two CF Triple Combo Regimens

Cystic Fibrosis

Vertex Pharmaceuticals has selected two of its next-generation correctors, VX-659 and VX-445, for Phase 3 trial development as part of two triple combination regimens for the treatment of cystic fibrosis. This ... Read more

February 1, 2018February 1, 2018

FDA Gives Aradigm Recommendations for Resubmitting Bronchiectasis Therapy Application

Bronchiectasis, News

The U.S. Food and Drug Administration has given Aradigm a list of suggestions for resubmitting an application for regulatory review of its bronchiectasis therapy Linhaliq. A review board had recommended against the FDA ... Read more

January 30, 2018January 30, 2018

FibroKine Inhaled Aerosol Delivery System for PF Awarded Early-stage Development Grant

Idiopathic Pulmonary Fibrosis, News

The University of Pittsburgh’s Center for Medical Innovation (CMI) awarded a total of $115,000 to advance the development of five proposed solutions to medical conditions. One of the recipients is ... Read more

January 18, 2018January 18, 2018

FDA Advisory Committee Does Not Recommend Approval of Inhalant Linhaliq

Bronchiectasis

The Antimicrobial Drugs Advisory Committee (ADAC) of the U.S. Food and Drug Administration (FDA) did not recommend approval of Aradigm’s Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients ... Read more

December 4, 2017December 4, 2017

FDA Advisory Group Sets Jan. 11 Review Date for Linhaliq, Potential Non-CF Bronchiectasis Therapy

Bronchiectasis, News

A committee of the U.S. Food and Drug Administration (FDA) will meet next month to review an application for Linhaliq to be approved for the treatment of patients with non-cystic fibrosis bronchiectasis ... Read more

October 18, 2017October 18, 2017

New Blocker of TGF-β1 Shows Promise as Potential Therapy for IPF Patients

Idiopathic Pulmonary Fibrosis, News

Blocking TGF-β1 — a known signaling pathway involved in tissue fibrosis — by compounds called trihydrophenolics halted fibrosis development and tissue stiffness in animal models of pulmonary fibrosis, new research shows. The ... Read more

September 12, 2017September 12, 2017

Inventiva Announces Further Collaboration with Boehringer Ingelheim to Develop IPF Therapies

Idiopathic Pulmonary Fibrosis, News

Inventiva Pharma recently announced that Boehringer Ingelheim will extend a collaboration with the company to further advance potential treatments for fibrotic conditions including idiopathic pulmonary fibrosis (IPF). The collaboration began in May 2016 as a research and ... Read more

September 8, 2017September 8, 2017

miRagen Therapeutics to Present New Promising Data on MRG-201 at ERS 2017

Idiopathic Pulmonary Fibrosis, News

miRagen Therapeutics, a biopharmaceutical company involved in the discovery of RNA-based therapies, will present new preclinical safety and feasibility data for the therapy MRG-201 in the treatment of pulmonary fibrosis at the ... Read more

August 28, 2017August 28, 2017

PharmAkea Completes Phase 1 Clinical Trial of Pulmonary Fibrosis Therapy PAT-1251

Idiopathic Pulmonary Fibrosis, News

PharmaAkea has completed a Phase 1 clinical trial indicating that its PAT-1251 therapy binds with an enzyme associated with pulmonary fibrosis. That suggests that it could be an effective treatment for ... Read more